Clinical Trial Update: Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for exemestane combined with sunitinib in metastatic breast cancer; trial phases 1 and 2 were terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Sutent (sunitinib)

Snippet

Sponsor: Baylor Breast Care Center | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-05-28